News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Plunges on Slow Sales, Plans "Across the Board" Layoffs



8/4/2011 7:22:01 AM

This year was supposed to be one of meteoric growth for Dendreon. Seattle's largest biotech company already had rocketed in less than two years from 180 employees to about 2,000. It was in the midst of rolling out its prostate-cancer treatment, Provenge, after years of gains, setbacks and delays. JPMorgan's biotech team proclaimed the stock "our top pick for 2011." Then Wednesday, it fell swiftly out of favor. Dendreon slashed its 2011 sales forecast, said layoffs are coming and posted second-quarter gross revenue of $51 million, about $7 million short of analysts' expectations.

Read at Seattle Times
Read at The Street.com
Read at Reuters
Read at Forbes


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES